Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.5 SEK | +0.98% |
|
+2.28% | +81.30% |
27/06 | Hansa Biopharma AB Announces Board Appointments | CI |
31/05 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
End-of-day quotes
Sector Other Biotechnology & Medical Research
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
30Cr | - | |||||
4.44TCr | - | |||||
3.98TCr | ||||||
3.77TCr | ||||||
3.15TCr | - | |||||
2.7TCr |
- Stock Market
- Equities
- HNSA Stock
- Charts Hansa Biopharma AB
- Sector Chart